NCT05347394View on ClinicalTrials.gov

A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 8, 2022

Primary Completion Date

April 14, 2023

Study Completion Date

April 14, 2023

Conditions
Acute Pain
Interventions
DRUG

VX-708

Solution or suspension for oral administration.

DRUG

Placebo

Placebo matched to VX-708 for oral administration.

Trial Locations (1)

Unknown

MAC Clinical Research, Manchester

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY